Angiotensin II receptor antagonists - antihypertensive agents
- 1 May 1997
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 6 (5) , 489-500
- https://doi.org/10.1517/13543784.6.5.489
Abstract
Blockade of the renin-angiotensin system (RAS) is now recognised as an effective approach for the treatment of hypertension and congestive heart failure (CHF). Today, it is possible to antagonise the effects of angiotensin II more specifically by blocking its receptors using non-peptide receptor antagonists. These compounds, which at first were used to identify the various subtypes of angiotensin II receptors, are now available clinically. Some of them have recently been launched on the market and several others are preregistered for the treatment of hypertension. These new molecules are as effective as angiotensin converting enzyme (ACE) inhibitors at lowering blood pressure in hypertensive patients, and appear to have similar systemic and renal haemodynamic properties in patients with CHF and renal diseases. Large-scale clinical trials such as the LIFE, the ELITE and the RENAAL studies are now underway to investigate the long-term benefits of one of these agents in hypertension, heart failure and Type I...Keywords
This publication has 26 references indexed in Scilit:
- Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)Published by Elsevier ,1997
- Effects of Losartan on a Background of Hydrochlorothiazide in Patients With HypertensionHypertension, 1995
- A Randomized, Placebo-Controlled, Double-Blind, Parallel Study of Various Doses of Losartan Potassium Compared With Enalapril Maleate in Patients With Essential HypertensionHypertension, 1995
- Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipne ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertensionThe American Journal of Cardiology, 1995
- Hemodynamic and Biochemical Effects of the AT 1 Receptor Antagonist Irbesartan in HypertensionHypertension, 1995
- TCV−116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive ratsLife Sciences, 1994
- Tetrahydroisoquinoline derivatives with AT2-specific angiotensin II reception binding inhibitory activityBioorganic & Medicinal Chemistry Letters, 1994
- Cloning and characterization of a human angiotensin II type 1 receptorBiochemical and Biophysical Research Communications, 1992
- Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research.Hypertension, 1991
- Reactive Hyperreninemia Is a Major Determinant of Plasma Angiotensin II During ACE InhibitionJournal of Cardiovascular Pharmacology, 1990